CClinicalTrials.gg
CompletedNCT06550297MTM4CVHUpdated Sep 1, 2026

Medically Tailored Meals for Cardiovascular Health

An interventional study of Medically Tailored Meals and Nutritional Counseling and Cardiovascular Health Promotion Educational Program in Diet, Healthy, HbA1c and Blood Pressure, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Columbia University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This randomized clinical trial (RCT) will investigate novel approaches to enhance effectiveness, engagement, reach, and cost-effectiveness of medically tailored meals (MTM) programs for promoting cardiovascular health, focusing on economically disadvantaged New York City neighborhoods with a disparate burden of multiple cardiometabolic diseases. The main questions the RCT aims to answer are:

  1. Does enhancing MTM programs, with culturally relevant cardiovascular health curriculum (including educational sessions on heart health, healthy diet, cooking demonstrations, recipes, gift bags with healthy ingredients and fresh produce, and addressing social needs) enhance program engagement and effectiveness in improving short-term healthy eating behaviors and clinical outcomes (HbA1c and blood pressure) among individuals with type 2 diabetes and elevated to high blood pressure who currently qualify for MTM programs?
  2. Is the MTM program coupled with the cardiovascular health curriculum effective for improving healthy eating behaviors and clinical outcomes (HbA1c and blood pressure) among individuals with type 2 diabetes and elevated to high blood pressure who do not currently qualify for MTM programs and is a gradual reduction of MTM dosing an effective and sustainable approach for expanding reach of these programs?

To answer question 1, 66 participants with type 2 diabetes and elevated to high blood pressure who currently qualify for MTM programs will be randomized into a group that receives the standard MTM program (10 MTMs/week for 8 months) or a group that receives the standard program plus the cardiovascular health curriculum.

To answer question 2, 110 participants with type 2 diabetes and elevated to high blood pressure who do not currently qualify for MTM programs (due to not having advanced disease with complications) will be randomized into a group that receives the standard MTM program (10 MTMs/week for 8 months) plus the cardiovascular health curriculum or a group that receives standard MTM program for the first 3 months followed by a gradual reduction in dosing of the MTMs by 50% over the remaining 5 months plus the CVH curriculum.

All participants will have their HbA1c and blood pressure measured and complete questionnaires about their diet quality, health and lifestyle behaviors, and program engagement and implementation at baseline, 3 months, and 8 months.

Read the detailed description

Medically tailored meals (MTMs) represent an integral in-kind intervention of the Food Is Medicine (FIM) initiative aimed at providing healthy food in a way that is integrated with the health care sector to prevent and manage chronic disease. MTMs are a promising approach to address diet-related cardiovascular inequities, because they collectively address food and nutrition insecurity, severe illness or chronic cardiometabolic disease, and challenges with activities of daily living such as shopping for or preparing meals in those with complex medical conditions. However, additional research is needed to determine how MTM programs could be enhanced to become more culturally and contextually responsive, increase engagement with these programs, enhance their effectiveness and sustainability, and expand their reach.

02

Conditions studied

  • Diet, Healthy
  • HbA1c
  • Blood Pressure

Keywords

  • Medically Tailored Meals
  • Type 2 Diabetes
  • High Blood Pressure
  • Multiple Cardiometabolic Morbidity
  • Food is Medicine
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 176 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.

Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For Cohort A (Individuals who currently qualify for MTMs)

Inclusion Criteria:

  1. Qualifying type 2 diabetes diagnosis (typically physician referred to the program due to more advanced disease with uncontrolled diabetes and complications)
  2. Hypertension diagnosis (systolic blood pressure greater than or equal to 130 mmHg and/or diastolic blood pressure greater than or equal to 80 mmHg) or elevated blood pressure (defined as systolic blood pressure greater than or equal to 120 mmHg)

Exclusion Criteria:

  1. Cancer diagnosis
  2. Undergoing cancer treatment
  3. Non-English or non-Spanish speaking
  4. Not cognitively able to complete study requirements
  5. Severe psychiatric disorders
  6. Inability to provide informed consent
  7. Health conditions that could prevent safe participation or impact study outcomes (e.g., substance use disorder, dialysis, neurodegenerative conditions)

For Cohort B (Individuals who do not currently qualify for MTMs)

Inclusion Criteria:

  1. Type 2 diabetes diagnosis (physician diagnosed or HbA1c greater than or equal to 6.5% or diabetes medication use)
  2. Hypertension diagnosis (systolic blood pressure greater than or equal to 130 mmHg and/or diastolic blood pressure greater than or equal to 80 mmHg or physician diagnosis or hypertension medication use) or elevated blood pressure (defined as systolic blood pressure greater than or equal to 120 mmHg)

Exclusion Criteria:

  1. Cancer diagnosis
  2. Undergoing cancer treatment
  3. Non-English or non-Spanish speaking
  4. Not cognitively able to complete study requirements
  5. Severe psychiatric disorders
  6. Inability to provide informed consent
  7. Health conditions that could prevent safe participation or impact study outcomes (e.g., substance use disorder, dialysis, neurodegenerative conditions)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Active comparator
    Arm 1: Cohort A (type 2 diabetes patients who currently qualify for MTMs) Active Comparator

    Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who currently qualify for medically tailored meals (MTMs). This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period.

    Behavioral: Medically Tailored Meals and Nutritional Counseling

  • Experimental
    Arm 2: Cohort A (type 2 diabetes patients who currently qualify for MTMs) Intervention

    Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who currently qualify for medically tailored meals (MTMs). This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period (same as Arm 1). In addition, they will receive a culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.

    Behavioral: Medically Tailored Meals and Nutritional Counseling · Behavioral: Cardiovascular Health Promotion Educational Program

  • Active comparator
    Arm 3: Cohort B (type 2 diabetes patients who do not currently qualify for MTMs) Active Comparator

    Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who do not currently qualify for medically tailored meals (MTM) programs. This arm will receive God's Love We Deliver's current MTM program, which consists of 10 home-delivered MTMs per week and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. In addition, they will receive a culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.

    Behavioral: Medically Tailored Meals and Nutritional Counseling · Behavioral: Cardiovascular Health Promotion Educational Program

  • Experimental
    Arm 4: Cohort B (type 2 diabetes patients who do not currently qualify for MTMs) Intervention

    Participants in this arm are type 2 diabetes patients with hypertension or elevated blood pressure who do not currently qualify for medically tailored meals (MTM) programs. This arm will receive the MTM program and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period but with a distinct MTM dosing schedule. They will receive the regular MTM schedule of 10 MTMs/week for the first 3 months of the intervention. After this initial period, MTM dosing will be gradually reduced by 1 MTM each month to a target schedule of 5 MTMs/week in the final month of the intervention. In addition, they will also receive the same culturally and contextually tailored cardiovascular health promotion program as Arms 2 and 3.

    Behavioral: Medically Tailored Meals and Nutritional Counseling · Behavioral: Cardiovascular Health Promotion Educational Program

Interventions

  • BehavioralMedically Tailored Meals and Nutritional Counseling

    God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.

  • BehavioralCardiovascular Health Promotion Educational Program

    Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients and fresh produce, and addressing social needs.

06

What researchers measure

Primary outcomes

  1. Change in Diet Quality

    The Mediterranean Eating Pattern for Americans (MEPA) scale, which captures adherence to a heart healthy dietary pattern, will be used to assess diet quality. The MEPA score ranges from 0-16 with higher scores indicating better diet quality. The change in MEPA scores from baseline to 8 months will be calculated and compared across randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months (primary endpoint)

  2. Change in HbA1c

    A fast and accurate HbA1c fingerstick test will assess changes in glycemic control from baseline to 3 months and 8 months (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months (primary endpoint)

  3. Change in systolic blood pressure

    The change office systolic blood pressure (mmHg) from baseline to follow-up at 3 months and 8 months will be calculated and compared across randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months (primary endpoint)

Secondary outcomes

  1. Mean Diet Quality

    The Mediterranean Eating Pattern for Americans (MEPA) scale, which captures adherence to a heart healthy dietary pattern, will be used to assess diet quality. The MEPA score ranges from 0-16 with higher scores indicating better diet quality. The mean MEPA scores at 3 months will be calculated and compared across randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  2. Mean HbA1c

    A fast and accurate HbA1c fingerstick test will assess glycemic control and mean HbA1c will be compared at 3 months and 8 months (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  3. Change in diastolic blood pressure

    The change office diastolic blood pressure (mmHg) from baseline to follow-up at 3 months and 8 months will be calculated and compared across randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  4. Mean systolic blood pressure

    Mean office systolic blood pressure (mmHg) at 3 months (mid-trial) and 8-months of follow-up (end of trial) calculated and compared across randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  5. Mean diastolic blood pressure

    Mean office diastolic blood pressure (mmHg) at 3 months (mid-trial) and 8-months of follow-up (end of trial) calculated and compared across randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  6. Acceptability of Implementation

    Acceptability will be measured by questionnaire. Items are adapted from the validated Acceptability of Implementation Measure (AIM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree." Higher scores indicate better intervention acceptability. The items are analyzed individually and not summed to a total score.

    Time frame: 8 months

  7. Feasibility of Implementation

    Feasibility will be measured by questionnaire using items adapted from the validated Feasibility of Implementation Measure (FIM) and rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree." Higher scores indicate better feasibility. The items are analyzed individually and not summed to a total score.

    Time frame: 8 months

  8. Appropriateness of Implementation

    Appropriateness will be measured by questionnaire. Items are adapted from the validated Implementation Appropriateness Measure (IAM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree." Higher scores indicate better appropriateness. The items are analyzed individually and not summed to a total score.

    Time frame: 8 months

  9. Satisfaction with Intervention

    Satisfaction with the intervention components will be measured by questionnaire. Participants will rate their satisfaction with intervention by indicating how likely they are to recommend it to others on a 10-point scale with higher scores indicating greater satisfaction (net promoter score). They will also be asked to rate the quality of the intervention as poor, fair, good, very good, or excellent. The items are analyzed individually and not summed to a total score.

    Time frame: 8 months

  10. Food Insecurity

    The USDA Household Food Security Survey (FSSM-6 item) will be administered at baseline, 3 months, and 8 months. The scores range from 0-6 such that a score of 0-1 indicates high or marginal food security, 2-4 indicates low food security, and 5-6 indicates very low food security. Changes in the score from baseline to follow up at 3 month and 8 months will be evaluated. In addition differences in mean scores will be compared across the randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 month, 8 months

  11. Nutrition Insecurity

    The Gretchen Swanson 4-item nutrition screener will be administered at baseline, 3 months, and 8 months (score range: 0-4 with higher scores indicating higher nutrition security). Changes in the score from baseline to follow up at 3 month and 8 months will be evaluated. In addition differences in mean scores will be compared across the randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  12. Sleep Health

    Sleep duration and quality will be measured using the Pittsburgh Sleep Quality Index (PSQI, score range: 0-21). Changes in self-reported habitual hours of sleep and the PSQI score from baseline to follow up at 3 month and 8 months will be evaluated. In addition differences in mean sleep duration and PSQI scores will be compared across the randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 month, 8 months

  13. Self-rated health

    Participant will rate their health as excellent, very good, good, fair, or poor at baseline, 3 months, and 8 months. Changes in self-rated health from baseline to follow up at 3 month and 8 months as well as the differences in mean self-rated health will be compared across the randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 months, 8 months

  14. General Health Status

    The EuroQoL 5-Dimension 5-Level (EQ-5D-5L) will be used to measure general health status and quality of life. This will be captured based on five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Based on the participant's response for reach dimension they will receive a 1-digit number, and the digits for the five dimensions will be combined into a 5-digit number that describes the patient's health state. This study will evaluate changes in this measure from baseline to follow up at 3 month and 8 months. In addition, differences in mean scores will be compared across the randomization arms (comparing Arm 1 vs. Arm 2 and Arm 3 vs. Arm 4).

    Time frame: baseline, 3 month, 8 months

07

Study locations

1 site
  • Columbia University Mailman School of Public Health
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: No — Data will be shared de-identified and in aggregate, consistent with the American Hospital Association Healthcare x Food requirements.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06550297
Lead sponsor
Columbia University
Collaborators
American Heart Association
Responsible party
Nour Makarem, PhD (Assistant Professor of Epidemiology, Columbia University) — Principal investigator
First posted
Aug 13, 2024
Start date
Aug 28, 2024
Primary completion
Jun 5, 2026
Completion
Jun 5, 2026
Last update
Sep 1, 2026

Study contacts

Nour Makarem, PhD, FAHA
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion